Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results-Reference-Cited by-同舟云学术

Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results

Published:2006 Issue:11 Volume:12 Page:1640-1648
ISSN:1527-6465
Container-title:Liver Transplantation
language:en
Short-container-title:Liver Transpl

Author:

Levy Gary,Schmidli Heinz,Punch Jeffrey,Tuttle-Newhall Elizabeth,Mayer David,Neuhaus Peter,Samuel Didier,Nashan Bjorn,Klempnauer Juergen,Langnas Alan,Calmus Yvon,Rogiers Xavier,Abecassis Michael,Freeman Richard,Sloof Maarten,Roberts John,Fischer Lutz

Publisher

Wiley

Subject

Transplantation,Hepatology,Surgery

Reference35 articles.

1. Recent Advances in Liver Transplantation

2. Liver transplantation

3. New immunosuppressive strategies in liver transplantation: balancing efficacy and toxicity

4. Immunosuppressive therapy in liver transplantation

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring in kidney and liver transplantation: current advances and future directions;Expert Review of Clinical Pharmacology;2024-05-16

2. How to prevent chronic kidney disease after liver transplantation?;Annals of Liver Transplantation;2024-05-16

3. Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation;Cancers;2024-03-22

4. Post Liver Transplant Renal Dysfunction—Evaluation, Management and Immunosuppressive Practice;Journal of Clinical and Experimental Hepatology;2024-03

5. Drug Interactions and Safe Prescription Writing for Liver Transplant Recipients;Journal of Clinical and Experimental Hepatology;2023-09